Novo Nordisk – major shareholder announcement
15 March 2022 - 1:51AM
Novo Nordisk – major shareholder announcement
Bagsværd,
Denmark,
14 March
2022 – Novo Nordisk today
announced that the company has been notified by BlackRock,
Inc. (Blackrock) that Blackrock as of 8 March 2022 holds B shares
equal to below 5% of the entire share capital of Novo Nordisk. The
announcement is in accordance with section 30 of the Danish Capital
Markets Act.
The total B shares according to section 38 of the Danish Capital
Markets Act, and other financial instruments according to section
39(2)(1) of the Danish Capital Markets Act and financial
instruments with similar effects according to section 39(2)(2) of
the Danish Capital Markets Act held by Blackrock correspond to
below 5% of the entire share capital and below 5% of the voting
rights.
For a full chain of controlled undertakings through which the
voting rights and/or the financial instruments are held, please see
the annex.
About Novo NordiskNovo Nordisk
is a leading global healthcare company, founded in 1923 and
headquartered in Denmark. Our purpose is to drive change to defeat
diabetes and other serious chronic diseases such as obesity and
rare blood and endocrine disorders. We do so by pioneering
scientific breakthroughs, expanding access to our medicines and
working to prevent and ultimately cure disease. Novo Nordisk
employs about 47,800 people in 80 countries and markets its
products in around 170 countries. Novo Nordisk's B shares are
listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the
New York Stock Exchange (NVO).
Further information
| Media: |
|
|
| Ambre Brown
Morley |
+45 3079 9289 |
abmo@novonordisk.com |
| Michael Bachner
(US) |
+1 609 664
7308 |
mzyb@novonordisk.com |
| |
|
|
|
Investors: |
|
|
| Daniel Muusmann
Bohsen |
+45 3075
2175 |
dabo@novonordisk.com |
| Ann Søndermølle
Rendbæk |
+45 3075
2253 |
arnd@novonordisk.com |
| David Heiberg
Landsted |
+45 3077
6915 |
dhel@novonordisk.com |
| Jacob Martin
Wiborg Rode |
+45 3075
5956 |
jrde@novonordisk.com |
| Mark Joseph Root
(US) |
+1 848 213
3219 |
mjhr@novonordisk.com |
Company announcement No 23 / 2022
Annex
|
Name |
% of voting rights if it equals or is higher than the notifiable
threshold |
% of voting rights through financial instruments if it equals or is
higher than the notifiable threshold |
Total of both if it equals or is higher than the notifiable
threshold |
|
BlackRock Japan Co., Ltd. |
|
|
Below 5% |
|
BlackRock Investment Management, LLC |
|
|
Below 5% |
|
BlackRock Investment Management (UK) Limited |
|
|
Below 5% |
|
BlackRock Investment Management (Australia) Limited |
|
|
Below 5% |
|
BlackRock International Limited |
|
|
Below 5% |
|
BlackRock Institutional Trust Company, National Association |
|
|
Below 5% |
|
BlackRock Fund Advisors |
|
|
Below 5% |
|
BlackRock Financial Management, Inc. |
|
|
Below 5% |
|
BlackRock Asset Management North Asia Limited |
|
|
Below 5% |
|
BlackRock Asset Management Deutschland AG |
|
|
Below 5% |
|
BlackRock Asset Management Canada Limited |
|
|
Below 5% |
|
BlackRock Advisors, LLC |
|
|
Below 5% |
|
BlackRock Advisors (UK) Limited |
|
|
Below 5% |
|
BlackRock (Singapore) Limited |
|
|
Below 5% |
|
BlackRock Asset Management Ireland Limited |
|
|
Below 5% |
|
Aperio Holdings, LLC |
|
|
Below 5% |
- CA220314_Major_shareholder_information
Novo Nordisk (TG:NOVC)
Historical Stock Chart
From May 2024 to Jul 2024
Novo Nordisk (TG:NOVC)
Historical Stock Chart
From Jul 2023 to Jul 2024
